

In the Claims:

Amend claims 16, 26 and 28 as follows:

Sub  
D1  
B2

16. (Amended) A transdermal therapeutic system with a content of a first active ingredient; said first active ingredient comprising at least one of candesartan and one of its pharmaceutically suitable esters or salts.

Sub  
D2  
B3

26. (Amended) The transdermal therapeutic system of claim 23 wherein the system is a matrix system comprising:

- an impermeable covering layer;
- at least one active ingredient-containing contact adhesive matrix layer or at least one ingredient-containing matrix layer coated with a contact adhesive;
- a detachable protective layer; and
- an active ingredient comprising at least one of candesartan and one of its pharmaceutically acceptable esters or salts.

Sub  
D3  
B4

28. (Amended) The transdermal therapeutic system of claim 23 wherein the membrane system comprises:

- an impermeable covering layer;
- an active ingredient-containing reservoir or an active ingredient-containing reservoir layer;
- a microporous or semipermeable membrane;
- an optional contact adhesive layer; and
- an active ingredient comprising at least one of candesartan and one of its pharmaceutically acceptable esters or salts.

**BEST AVAILABLE COPY**